MEDI-528, now recognized as enokizumab , represents a groundbreaking treatment targeting the insulin-like growth factor 1 receptor , a vital protein implicated in several epidermal conditions . Early trial https://teganomuw677312.aboutyoublog.com/52397174/enokizumab-a-deep-dive-into-medi-528-and-its-potential